(Q33682356)

28 July 2017

0 references

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials (English)

1 reference

28 July 2017

1 reference

Yong Bing Cao

1

1 reference

28 July 2017

Jun Dong Zhang

series ordinal

2

1 reference

28 July 2017

Hui Shen

series ordinal

3

1 reference

28 July 2017

Yuan Ying Jiang

series ordinal

4

1 reference

28 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20812009

5 July 2024

publication date

2 September 2010

1 reference

full work available at URL

28 July 2017

http://link.springer.com/content/pdf/10.1007/s00228-010-0889-z.pdf

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00228-010-0889-Z

http://link.springer.com/article/10.1007/s00228-010-0889-z/fulltext.html

5 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00228-010-0889-Z

http://link.springer.com/content/pdf/10.1007/s00228-010-0889-z

5 July 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00228-010-0889-Z

European Journal of Clinical Pharmacology

5 July 2024

published in

1 reference

28 July 2017

volume

66

1 reference

28 July 2017

issue

11

1 reference

28 July 2017

page(s)

1099-1108

1 reference

Why sources of heterogeneity in meta-analysis should be investigated

28 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-010-0889-Z

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

12 December 2020

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

12 December 2020

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

12 December 2020

Assessing the quality of randomized controlled trials. Current issues and future directions

1 reference

12 December 2020

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

1 reference

12 December 2020

Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement

1 reference

12 December 2020

Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty

1 reference

12 December 2020

Roentgen diagnosis of venous thrombosis in the leg

1 reference

12 December 2020

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

12 December 2020

Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment

1 reference

12 December 2020

Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

12 December 2020

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

1 reference

12 December 2020

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

1 reference

12 December 2020

The importance of quality of primary studies in producing unbiased systematic reviews

1 reference

12 December 2020

Extended thromboprophylaxis after hip or knee replacement

1 reference

12 December 2020

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

12 December 2020

Summing up evidence: one answer is not always enough.

1 reference

12 December 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1021872869

0 references

1 reference